MedTrace Logo

Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?

NCT03681938 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2018-09-24

No results posted yet for this study

Summary

The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion.

This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.

Conditions

  • Lymphoma, B-Cell

Interventions

PROCEDURE

Autograft

Autograft

Sponsors & Collaborators

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • BOUABDALLAH Réda, MD · Institut Paoli-Calmettes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-03
Primary Completion
2019-07-28
Completion
2019-07-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03681938 on ClinicalTrials.gov